Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials

@article{Roustit2013Phosphodiesterase5IF,
  title={Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials},
  author={Matthieu Roustit and Sophie Blaise and Yannick Allanore and Patrick H. Carpentier and Evren Caglayan and Jean-Luc Cracowski},
  journal={Annals of the Rheumatic Diseases},
  year={2013},
  volume={72},
  pages={1696 - 1699}
}
Introduction Recent controlled trials have assessed the efficacy of phospodiesterase-5 (PDE-5) inhibitors in secondary Raynaud's phenomenon (RP). However, the conclusions are conflicting, and whether these drugs are effective remains unclear. The objective of this meta-analysis was to determine the efficacy of PDE-5 inhibitors on Raynaud's Condition Score (RCS) and frequency and duration of attacks. Methods A systematic review of articles was performed (sources included Medline, Embase, Web of… 
Effects of phosphodiesterase type 5 inhibitors on Raynaud’s phenomenon
TLDR
PDE-5Is significantly increased fingertip temperature within 120 min, and the effect of vardenafil lasted for 12 weeks under daily use, indicating they were safe and would be an effective treatment for RP with CTDs.
Evidence for the Use of Epoprostenol to Treat Raynaud’s Phenomenon With or Without Digital Ulcers
TLDR
There was no consistent measurement of efficacy utilized, but improvements in hand temperature, RP attack duration and frequency were commonly associated with IV epoprostenol treatment (5 trials), and there were conflicting data regarding effect sustainability, with 5 trials showing long-term effects and 3 showing immediate effects.
Use of nitroglycerin ointment to treat primary and secondary Raynaud’s phenomenon: a systematic literature review
TLDR
Nitroglycerin ointment is commercially available, and it has less systemic side effects than other topical formulations, and its role in the treatment of RP has not yet been completely established.
Therapeutic implications from the pathogenesis of Raynaud’s phenomenon
  • A. Herrick
  • Medicine
    Expert review of clinical immunology
  • 2017
TLDR
This review discusses how increased understanding of the pathogenesis of RP has driven and is driving new approaches to therapy, and how the authors are now better able to predict which patients presenting with RP are likely to have an underlying disease requiring specific intervention.
In Raynaud phenomenon, on-demand sildenafil did not reduce disability or frequency or duration of attacks
TLDR
Aggregated results showed that on-demand sildenafil did not reduce disability or frequency or duration of attacks compared with placebo, and aggregated data for data aggregated across n-of-1 trials using a Bayesian analysis were reported.
Treatment options in Raynaud's phenomenon
TLDR
The aim of this review is to provide the readers with the background to understand the rationale for the current treatments used in patients with RP, to critically appraise the evidence for these treatments and to discuss future treatment approaches.
The clinical effects of l‐arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud's phenomenon
TLDR
While there is no established dosing regimen, studies of oral l_arginine in secondary RP suggest that divided dosing may begin at 1_2 g/day and may be titrated up to 10 g/ day.
Drug Treatment of Raynaud’s Phenomenon
TLDR
Sometimes Raynaud’s Phenomenon (RP) is symptomatic enough to warrant pharmacological treatment, and in mild RP, PDE5 inhibitors or losarten (an angiotension II inhibitor) or fluoxetine (a selective serotonin reuptake inhibitor) may be considered with some positive randomized controlled trial data.
...
...

References

SHOWING 1-10 OF 20 REFERENCES
Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication
TLDR
Based on current data from small clinical trials, open-label pilot studies and case series and reports, phosphodiesterase 5 inhibitors may help some patients with very serious Raynaud's phenomenon.
Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication.
TLDR
Based on current data from small clinical trials, open-label pilot studies and case series and reports, phosphodiesterase 5 inhibitors may help some patients with very serious Raynaud's phenomenon.
Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
TLDR
Tadalafil appears to be safe and well tolerated but lacks efficacy in comparison to placebo as a treatment for RP secondary to SSc and there were no statistically significant differences in Raynaud Condition Score (RCS), frequency of RP episodes, or duration ofRP episodes between treatment groups.
Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
TLDR
The results of this study suggest that the efficacy of calcium-channel blockers in reducing the severity and frequency of ischemic attacks in RP secondary to SSc is moderate at best, and a further large, randomized controlled trial needs to be conducted.
Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.
TLDR
Tadalafil as add-on therapy improves symptoms of RP, heals and prevents new DUs and improves QoL in patients with resistant secondary RP.
Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.
TLDR
Findings indicate that modified-release sildenafil reduced attack frequency in patients with RP secondary to lcSSc and was well tolerated.
Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy
TLDR
Sildenafil is an effective and well-tolerated treatment in patients with Raynaud’s phenomenon, and capillary blood flow velocity increased in each individual patient, and the mean capillary flow velocity of all patients more than quadrupled after treatment with sildanafil.
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
TLDR
Evidence-based, consensus-derived recommendations for the treatment of systemic sclerosis are useful for rheumatologists to help guide treatment for patients with SSc and may also help to define directions for future clinical research in SSc.
The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial
TLDR
The MID and PASS estimates for RCS are 14–15 points for improvement and 34 points, respectively, on a 0–100 scale in a large RCT of patients with active RP, which can aid in interpreting RCS in future RP trials.
Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice.
TLDR
It is found that inhibition of Syk in MRL/lpr and BAK/BAX mice prevented the development of skin disease and significantly reduced established skin disease, and Syk inhibition reduced the size of the spleen and lymph nodes, suppressed theDevelopment of renal disease and suppressed established renal disease.
...
...